⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210361 | 0.79 | DGAT1 (0.50) | — | |
| SCHEMBL12654680 | 0.75 | PKM (0.43) | — | |
| SCHEMBL4763650 | 0.74 | — | — | |
| SCHEMBL6840349 | 0.74 | DGAT1 (0.39) | — | |
| SCHEMBL8173647 | 0.72 | — | — | |
| SCHEMBL6280144 | 0.72 | DGAT1 (0.42) | — | |
| SCHEMBL6065154 | 0.71 | — | — | |
| SCHEMBL20852844 | 0.71 | — | — | |
| SCHEMBL11675279 | 0.71 | — | — | |
| SCHEMBL677960 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201236-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| WO-2021209427-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-21 | — | — | WO | disclosed |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170065585-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2015050989-A2 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CS THERAPEUTICS INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8933052-B2 | Uracyl spirooxetane nucleosides | JANSSEN PRODUCTS, LP (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130217648-A1 | Uracyl Spirooxetane Nucleosides | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| US-8481510-B2 | Uracyl spirooxetane nucleosides | JANSSEN PRODUCTS, LP (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120065156-A1 | Uracyl Spirooxetane Nucleosides | TIBOTEC BVBA (BE) | 2012-03-15 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7939553-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |